Back to News
Raymond James cuts Dyne Therapeutics price target on DM1 trial risk
Source: Investing.com
No news content was provided; the article text contains only a 403 access error.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Morning Bid: $100 Brent in sight, yen defies gravity
- CNBC Daily Open: Sanctions, strikes and the road to $100 oil
- Nvidia Earnings Blow Everyone Away
- Oil extends rally, Brent nears $100/bbl as U.S.-Iran tensions escalate
- China's EV makers shift gears to focus on humanoids as car market slows
- US destroys five Iranian tankers, Iran retaliates with attacks on Jordan